Literature DB >> 22752855

MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.

Samantha Jilek1, Myriam Schluep, Giuseppe Pantaleo, Renaud A Du Pasquier.   

Abstract

Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS). Myelin oligodendrocyte glycoprotein (MOG) and myelin oligodendrocyte basic protein (MOBP) were both shown to be highly encephalitogenic in animal models of MS. In contrast, the association of MOG- and MOBP-specific humoral or cellular immune responses and MS in humans is far less established. In this study, we sought to analyse MOG- and MOBP-specific T-cell responses in a large cohort of patients with various stages of the disease. Patients with other neurological diseases and healthy subjects were enrolled to serve as control study subjects. We determined the proliferation and the secretion of IFN-γ secretion in our cohort. We found that MOG-specific T-cell responses were higher and more frequent as compared to MOBP-specific ones. However, both MS patients and control study subjects had similar myelin-specific T-cell responses at the periphery, thus calling for more precise studies at CNS level.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752855     DOI: 10.1007/s10072-012-1144-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  13 in total

Review 1.  Migration, maintenance and recall of memory T cells in peripheral tissues.

Authors:  David L Woodland; Jacob E Kohlmeier
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

2.  Intrathecal immune responses to EBV in early MS.

Authors:  Emilie Jaquiéry; Samantha Jilek; Myriam Schluep; Pascal Meylan; Andreas Lysandropoulos; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Eur J Immunol       Date:  2010-03       Impact factor: 5.532

3.  Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis.

Authors:  A Holz; B Bielekova; R Martin; M B Oldstone
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

4.  Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Authors:  M Reindl; C Linington; U Brehm; R Egg; E Dilitz; F Deisenhammer; W Poewe; T Berger
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

5.  Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.

Authors:  Samantha Jilek; Emilie Jaquiéry; Hans H Hirsch; Andreas Lysandropoulos; Mathieu Canales; Laurence Guignard; Myriam Schluep; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Lancet Neurol       Date:  2010-01-29       Impact factor: 44.182

6.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

7.  The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501.

Authors:  Nicole Kerlero de Rosbo; Joel F Kaye; Miriam Eisenstein; Itzhack Mendel; Romana Hoeftberger; Hans Lassmann; Roni Milo; Avraham Ben-Nun
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

8.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

Authors:  Thomas Berger; Paul Rubner; Franz Schautzer; Robert Egg; Hanno Ulmer; Irmgard Mayringer; Erika Dilitz; Florian Deisenhammer; Markus Reindl
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

9.  Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.

Authors:  Laureline Berthelot; David-Axel Laplaud; Ségolène Pettré; Caroline Ballet; Laure Michel; Sophie Hillion; Cécile Braudeau; Francine Connan; Fabienne Lefrère; Sandrine Wiertlewski; Jean-Gérard Guillet; Sophie Brouard; Jeannine Choppin; Jean-Paul Soulillou
Journal:  Eur J Immunol       Date:  2008-07       Impact factor: 5.532

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  3 in total

1.  Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.

Authors:  Michael C Levin; Sangmin Lee; Lidia A Gardner; Yoojin Shin; Joshua N Douglas; Chelsea Cooper
Journal:  J Clin Cell Immunol       Date:  2013-06-30

Review 2.  Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis.

Authors:  Judith M Greer
Journal:  Mult Scler Int       Date:  2013-11-07

3.  Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord.

Authors:  Wojciech Dabrowski; Jacek M Kwiecien; Radoslaw Rola; Michal Klapec; Greg J Stanisz; Edyta Kotlinska-Hasiec; Wendy Oakden; Rafal Janik; Margaret Coote; Benicio N Frey; Waldemar A Turski
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.